The investigators will conduct an 8-week, non-randomized, open-label study of brexpiprazole
in 20 persons with bipolar I or II disorder, depressed mood state. Primary aim will be to
assess if brexpiprazole is associated with a reduction in depressive symptom severity using
the Montgomery-Asberg Depression Rating Scale (MADRS). Secondary aims will include an
assessment of the following in patients with bipolar disorder taking brexpiprazole: manic
symptoms, cognition, safety and tolerability of brexpiprazole, and quality of life.
Subjects will be discontinued from the study if any of the following conditions occurs:
change in diagnosis to other than bipolar I or II disorder, development of active suicidal or
homicidal ideation with plan and intent, worsening of mood symptoms, that in the opinion of
the investigators requires discontinuation, pregnancy, development of severe life-threatening
medical condition, involuntary psychiatric hospitalization or incarceration.